Method of selection for treatment of subjects at risk of invasive breast cancer
AssigneePrelude Corporation
InventorTroy M. Bremer
Life of this patent
Estimating the term…
Abstract
The present disclosure provides compositions and methods for the treatment of subjects having a risk of invasive breast cancer. In some embodiments, these aspects allow for the pairing of the proper treatment option for the particular subject. In some embodiments, this allows for identifying subjects who, while at risk for invasive breast cancer, will not normally respond to radiation therapy, and can instead receive an alternative therapy, such as a HER2 antibody.
Claims24
A method of treating a subject, the method comprising:
- identifying a subject with DCIS that has an elevated level of activity in a k-ras pathway;
- and
- administering an aggressive breast cancer therapy to the subject.
A method of treating a subject, the method comprising:
- identifying a subject with DCIS, that is HER2 positive and SIAH2 positive;
- and
- administering an aggressive breast cancer therapy to the subject, wherein the aggressive breast cancer therapy is aggressive radiation therapy or aggressive non-radiation therapy.
(canceled)
A method of identifying a subject for an aggressive cancer therapy, the method comprising:
- identifying a subject with DCIS at an elevated risk of invasive breast cancer;
- and
- determining if the subject is HER2 and SIAH2 positive,
- wherein if the subject is HER2 and SIAH2 positive, administering an aggressive therapy to the subject,
- wherein the aggressive therapy:
- a) is not radiation therapy;
- b) is aggressive radiation therapy;
- c) is chemotherapy;
- d) is a therapy that comprises an anti-HER2 antibody;
- or
- e) is selected from the group consisting of:
- an antibody to HER2 or Trastuzumab.
(canceled)
A method for treating a subject, said method comprising:
- providing a DCIS sample from a subject;
- analyzing the DCIS sample for a level of at least PR and HER2, and at least either:
- a) analyzing the sample for at least SIAH2, or
- b) analyzing the sample for at least FOXA1;
- and
- providing a prognosis based upon at least PR, HER2 and SIAH2 or based upon at least PR and FOXA1,
- wherein if the sample is PR positive, further analyzing the sample for a level of COX2, wherein COX2 positive with at least FOXA1 positive indicates a high risk of invasive breast cancer,
- determining if the subject is HER2 positive;
- and
- administering an aggressive therapy to the subject if the subject is HER2 positive,
- wherein the aggressive therapy is more aggressive than the standard of care therapy.
A method of providing a benefit of radiation therapy, the method comprising:
- identifying a subject with DCIS at elevated risk of invasive breast cancer;
- and
- administering radiation therapy to the subject if the subject is HER2 negative and administering aggressive radiation therapy or aggressive non-radiation therapy to the subject if the subject is HER2 positive.
-17. (canceled)
(canceled)
A kit comprising:
- a first detectable binding agent specific for HER2;
- and
- a second detectable binding agent specific for SIAH2.
Dependencies are inferred from the claim text.